DeepMed Research

Evelo Biosciences, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 2015-01-01

Employees: 66

Market Cap: -

Website: http://www.evelobio.com

Clinical Trials

Evaluation of the Immunopharmacology of EDP1815 and EDP2939

Phase 1

Completed

Conditions: KLH and Imiquimod Induced Skin Inflammation in Healthy Volunteers

Interventions: Drug: EDP2939
Drug: EDP1815
Drug: Placebo oral capsule

First Posted Date: 2023-01-12

Last Posted Date: 2023-05-19

Lead Sponsor: Evelo Biosciences, Inc.

Target Recruit Count: 38

Registration Number: NCT05682222

Locations: 🇳🇱
Centre for Human Drug Research, Leiden, Netherlands

A Long-Term Extension Trial in Participants With Atopic Dermatitis Who Participated in Previous EDP1815 Trials

Phase 2

Terminated

Conditions: Atopic Dermatitis

Interventions: Drug: EDP1815

First Posted Date: 2022-06-30

Last Posted Date: 2023-09-07

Lead Sponsor: Evelo Biosciences, Inc.

Target Recruit Count: 287

Registration Number: NCT05439941

Locations: 🇺🇸
USA -101, Fort Lauderdale, Florida, United States
🇧🇬
BGR-105, Pleven, Bulgaria
🇺🇸
USA-121, Columbus, Ohio, United States

and more 51 locations

A Study Investigating the Effect of EDP1815 in the Treatment of Mild, Moderate and Severe Atopic Dermatitis

Phase 2

Completed

Conditions: Atopic Dermatitis

Interventions: Drug: EDP1815
Drug: Placebo

First Posted Date: 2021-11-16

Last Posted Date: 2023-08-16

Lead Sponsor: Evelo Biosciences, Inc.

Target Recruit Count: 421

Registration Number: NCT05121480

Locations: 🇺🇸
USA-112, Fountain Valley, California, United States
🇺🇸
USA-114, Newport Beach, California, United States
🇺🇸
USA-105, Miramar, Florida, United States

and more 56 locations

Scintigraphy Study to Evaluate the Gastrointestinal Behavior of EDP1815 Oral Dosage Forms

Phase 1

Completed

Conditions: Disintegration
Healthy

Interventions: Drug: EDP1815 capsule A
Drug: EDP1815 capsule B
Drug: EDP1815 tablet

First Posted Date: 2021-10-04

Last Posted Date: 2023-03-24

Lead Sponsor: Evelo Biosciences, Inc.

Target Recruit Count: 48

Registration Number: NCT05066373

Locations: 🇬🇧
BDD Pharma Ltd, Glasgow, Scotland, United Kingdom

Study in Healthy Participants and Participants With Moderate Atopic Dermatitis & Optionally, Moderate Psoriasis, and/or Mild Asthma

Phase 1

Completed

Conditions: Atopic Dermatitis
Asthma
Psoriasis

Interventions: Drug: EDP1867
Drug: Placebo

First Posted Date: 2021-06-15

Last Posted Date: 2022-10-07

Lead Sponsor: Evelo Biosciences, Inc.

Target Recruit Count: 52

Registration Number: NCT04927195

Locations: 🇬🇧
MAC Clinical Research Manchester, Manchester, Greater Manchester, United Kingdom
🇬🇧
Medicines Evaluation Unit (MEU), Manchester, Greater Manchester, United Kingdom
🇬🇧
MAC Clinical Research, Leeds, West Yorkshire, United Kingdom

A Phase 2 Study Investigating the Effect of EDP1815 in the Treatment of Mild to Moderate Plaque Psoriasis

Phase 2

Completed

Conditions: Plaque Psoriasis
Psoriasis

Interventions: Drug: EDP1815
Drug: Placebo

First Posted Date: 2020-10-26

Last Posted Date: 2022-12-19

Lead Sponsor: Evelo Biosciences, Inc.

Target Recruit Count: 249

Registration Number: NCT04603027

Locations: 🇺🇸
Synexus Clinical Research US, Inc. - St. Petersburg, Saint Petersburg, Florida, United States
🇵🇱
Synexus - Gdynia, Gdynia, Pomorskie, Poland
🇵🇱
Synexus - Warszawa, Warszawa, Poland

and more 23 locations

Safety and Efficacy of EDP1815 in the Treatment of Patients Hospitalized With COVID-19 Infection

Phase 2

Terminated

Conditions: Covid19

Interventions: Drug: EDP1815
Drug: Placebo

First Posted Date: 2020-07-28

Last Posted Date: 2022-12-19

Lead Sponsor: Evelo Biosciences, Inc.

Target Recruit Count: 16

Registration Number: NCT04488575

Locations: 🇺🇸
DHR Health Institute, Edinburg, Texas, United States
🇹🇷
Hacettepe University Adult Hospital, Ankara, Turkey
🇺🇸
The University Hospital, Newark, New Jersey, United States

and more 1 locations

A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors

Phase 1

Completed

Conditions: Colorectal Cancer Metastatic
Triple Negative Breast Cancer
Non Small Cell Lung Cancer
Bladder Cancer
GastroEsophageal Cancer
Renal Cell Carcinoma
MSI-H

Interventions: Biological: EDP1503
Biological: Pembrolizumab

First Posted Date: 2018-12-14

Last Posted Date: 2023-03-24

Lead Sponsor: Evelo Biosciences, Inc.

Target Recruit Count: 69

Registration Number: NCT03775850

Locations: 🇺🇸
Highlands Oncology Group, Rogers, Arkansas, United States
🇨🇦
Jewish General Hospital, Montréal, Quebec, Canada
🇨🇦
CHU de Québec - Université Laval, Québec, Canada

and more 5 locations

A Study of EDP1815 in Healthy Participants and Participants With Mild to Moderate Psoriasis and Atopic Dermatitis

Phase 1

Completed

Conditions: Psoriasis
Atopic Dermatitis

Interventions: Drug: EDP1815
Drug: Placebo oral capsule
Drug: Placebo oral tablet

First Posted Date: 2018-11-07

Last Posted Date: 2022-01-10

Lead Sponsor: Evelo Biosciences, Inc.

Target Recruit Count: 204

Registration Number: NCT03733353

Locations: 🇬🇧
UK-7, Blackpool, United Kingdom
🇬🇧
UK-5, Liverpool, United Kingdom
🇬🇧
UK-8, Barnsley, United Kingdom

and more 6 locations

A Study of EDP1066 in Healthy Participants and Participants With Mild to Moderate Psoriasis and Atopic Dermatitis

Phase 1

Completed

Conditions: Atopic Dermatitis
Psoriasis

Interventions: Other: EDP1066
Drug: Placebo oral capsule

First Posted Date: 2018-06-01

Last Posted Date: 2021-11-09

Lead Sponsor: Evelo Biosciences, Inc.

Target Recruit Count: 114

Registration Number: NCT03542994

Locations: 🇬🇧
MAC Clinical Research, Stockton-on-Tees, United Kingdom
🇬🇧
University of Surrey Clinical Research Center, Guildford, Surrey, United Kingdom
🇬🇧
Royal Liverpool Clinical Research Unit, Liverpool, United Kingdom

and more 1 locations

Prev
1
Next

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy